Duchenne muscular dystrophy drug receives accelerated approval from FDA
The US Food and Drug Administration (Silver Spring, MD, USA) has granted accelerated approval for eteplirsen, making it the first drug treating the most common childhood form of muscular dystrophy to attain approval.
Please sign in or register for FREE
Sign in to MedChemNet
Register to MedChemNet
MedChemNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.